EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients ...

DelveInsight's Diabetic Macular Edema Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 13, 2025 /EINPresswire ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

At a single academic tertiary referral center, mild intraocular inflammation developed in four eyes following intravitreal ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...

The Brooklyn-based startup is specifically targeting people with macular degeneration. The degenerative eye disease affects roughly 13% of U.S. residents aged 40 and up, according to figures from ...

The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

The condition appears to be triggered when the optic nerve swells, choking off its blood supply because the nerve's pathway ...

macular edema caused by a blockage in the retinal vein diabetic retinopathy diabetic macular edema Eylea is also used to treat retinopathy of prematurity, an eye condition that can affect ...